• Sol-Gel Technologies’ third-quarter 2026 net loss narrowed 5% to $5.62 million, while revenue fell 90% to $41,000 year-over-year.
• Research and development expenses dropped 11% year-over-year to $5.12 million, primarily due to lower SGT-610 clinical trial expenses.
• Cash resources totaled $45.7 million at September 30, with funding expected to last into the first quarter of 2028.
• The pivotal SGT-610 Gorlin syndrome trial completed its last patient visit in September; top-line results are expected in late November 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120830PRIMZONEFULLFEED9876229) on November 12, 2026, and is solely responsible for the information contained therein.